Maximum Dose of Beta-Blockers in Cirrhosis

Introduction to Beta-Blocker Dosing

The maximum dose of beta-blockers in cirrhosis depends on the presence of ascites, with propranolol not exceeding 160 mg daily in patients with ascites and 320 mg daily in those without ascites, according to the Clinical and Molecular Hepatology guidelines 1
Nadolol is limited to 80 mg daily with ascites and 160 mg daily without ascites, as recommended by the Clinical and Molecular Hepatology guidelines 1

For patients without ascites, the maximum dose of propranolol is 320 mg daily, with a starting dose of 20-40 mg twice daily, and titration every 2-3 days until a target heart rate of 55-60 beats per minute is achieved, while maintaining a systolic blood pressure of ≥90 mmHg, as per the Clinical and Molecular Hepatology guidelines 1
In patients with ascites, the maximum dose of propranolol is reduced to 160 mg daily, and in those with spontaneous bacterial peritonitis, a low dose of 80 mg/day may be safer and is associated with improved survival, according to the Journal of Hepatology guidelines 1, 2

For patients without ascites, the maximum dose of nadolol is 160 mg daily, with a starting dose of 20-40 mg once daily, and titration every 2-3 days to target heart rate, as recommended by the Clinical and Molecular Hepatology guidelines 1
In patients with ascites, the maximum dose of nadolol is limited to 80 mg daily, with the same titration principles applying and careful monitoring, according to the Clinical and Molecular Hepatology guidelines 1

The starting dose of carvedilol is 6.25 mg once daily (or 3.125 mg twice daily), and it is not guided by heart rate, but carvedilol may be particularly deleterious in decompensated patients due to its additional alpha-1 blocking effects, and should be avoided or closely monitored in patients with refractory ascites, as warned by the Journal of Hepatology guidelines 1, 3, 2

Beta-blocker doses must be reduced or temporarily discontinued in patients with refractory ascites who develop systolic blood pressure <90 mmHg, serum creatinine >1.5 mg/dL, or serum sodium <130 mmol/L, as indicated by the Journal of Hepatology guidelines 3, 2

Close monitoring of blood pressure and renal function is crucial, with dose adjustment rather than complete discontinuation, to avoid worsening outcomes, as recommended by the Clinical and Molecular Hepatology and Journal of Hepatology guidelines 1, 3, 2
In advanced cirrhosis, prioritizing blood pressure and renal function monitoring over strict heart rate targets is essential, according to the Journal of Hepatology guidelines 3, 2
Abruptly stopping beta-blockers increases the risk of variceal bleeding and mortality, and if beta-blockers must be discontinued, endoscopic variceal ligation should be initiated as an alternative, as advised by the Clinical and Molecular Hepatology and Journal of Hepatology guidelines 1, 3